You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
The Tokyo-based firm is looking to expand into the US market following a recent ¥700 million ($6.6 million) Series B financing round.
An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.
The Bay Area firm has built on its enzymatic barcoding technology to deliver a high-throughput, synthetic long-read library preparation technique.
The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.